KEYTRUDA as Monotherapy Significantly Improved PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer Compared to Chemotherapy ...

Merck & Co Inc. MRK on Wednesday released topline data from the Phase 3 KEYNOTE‑C93 trial of Keytruda (pembrolizumab). Phase ...

US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® ...

Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.

Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has ...

Early chemotherapy discontinuation (>21 days before last pembrolizumab) in responders with ≥24-week clinical benefit showed ...

FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...

KEYNOTE-C93 demonstrated BICR-assessed PFS superiority for pembrolizumab monotherapy over platinum doublet chemotherapy in frontline dMMR advanced/recurrent endometrial cancer. Overall survival ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, after being recommended by reimbursement authority NICE. In final draft ...

Add Yahoo as a preferred source to see more of our stories on Google. Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness' top 10 healthcare stock picks. On June 25, Merck & Co., Inc.